# A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re

Source: https://onco.cc/trials/nct05730036/  
OnCo record `nct05730036` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Linvoseltamab, Elotuzumab, Pomalidomide in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.

## Summary

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT05730036 by Regeneron Pharmaceuticals, with 410 participants planned, started 2023-09-18 and due to reach its primary completion in 2033-04-19. Interventions recorded: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone. Conditions listed: Relapsed Refractory Multiple Myeloma (RRMM). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05730036
- Phase: 3
- Setting: An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 410

## Sources

- ClinicalTrials.gov NCT05730036: https://clinicaltrials.gov/study/NCT05730036

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Elotuzumab](https://onco.cc/drugs/elotuzumab/), [Linvoseltamab](https://onco.cc/drugs/linvoseltamab/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct05730036.json